Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
29.33
+1.46 (5.24%)
At close: May 12, 2025, 4:00 PM
28.00
-1.33 (-4.53%)
After-hours: May 12, 2025, 6:20 PM EDT
Avidity Biosciences Employees
Avidity Biosciences had 391 employees as of December 31, 2024. The number of employees increased by 138 or 54.55% compared to the previous year.
Employees
391
Change (1Y)
138
Growth (1Y)
54.55%
Revenue / Employee
$22,831
Profits / Employee
-$944,297
Market Cap
3.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 391 | 138 | 54.55% |
| Dec 31, 2023 | 253 | 67 | 36.02% |
| Dec 31, 2022 | 186 | 61 | 48.80% |
| Dec 31, 2021 | 125 | 54 | 76.06% |
| Dec 31, 2020 | 71 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNA News
- 4 days ago - Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 6 days ago - Avidity Biosciences to Participate in Upcoming Investor Conference - PRNewsWire
- 21 days ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire
- 6 weeks ago - Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - PRNewsWire
- 2 months ago - Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial - PRNewsWire
- 2 months ago - Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 2 months ago - Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases - PRNewsWire